Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients
NCT ID: NCT01957839
Last Updated: 2013-10-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
48 participants
INTERVENTIONAL
2010-03-31
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pretreatment group
doppler evaluation at pretreatment period
No interventions assigned to this group
posttreatment group
doppler evaluatıon in normoprolactinemia women who given cabergoline treatment
cabergoline treatment
cabergoline treatment for hyperprolactinemia group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cabergoline treatment
cabergoline treatment for hyperprolactinemia group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Use of drugs effecting vasculature such as hormonal therapy, oral contraceptives, antihypertensives
* Diseases like pelvic inflammatory disease and systemic hypertension
* Women with clinically overt or treated cardiovascular disease
* Concurrent illness other than hyperprolactinemia
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul Bakirkoy Maternity and Children Diseases Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Osman Aşıcıoğlu
sisli etfal teaching hospital department gynecology and obstetric
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Osman Temizkan, M.D.
Role: PRINCIPAL_INVESTIGATOR
SİSLİ ETFAL TEACHİNG HOSPİTAL
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sisli Etfal Teaching Hosital
Şişli, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi S, Okada Y, Hori T. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab. 2010 Jun;95(6):2672-9. doi: 10.1210/jc.2009-2605. Epub 2010 Mar 31.
Temizkan O, Temizkan S, Asicioglu O, Aydin K, Kucur S. Color Doppler analysis of uterine, spiral, and intraovarian artery blood flow before and after treatment with cabergoline in hyperprolactinemic patients. Gynecol Endocrinol. 2015 Jan;31(1):75-8. doi: 10.3109/09513590.2014.958989. Epub 2014 Sep 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OA8
Identifier Type: OTHER
Identifier Source: secondary_id
Aşıcıoğlu-08
Identifier Type: -
Identifier Source: org_study_id